Education
About Us
Working with TipRanks
Follow Us
Agios Pharmaceuticals (GB:0HB0)
:0HB0
0HB0 Stock Chart & Stats
Day’s Range― - ―
52-Week Range$27.37 - $62.60
Previous CloseN/A
Volume30.00
Average Volume (3M)269.00
Market Cap
$1.84B
Enterprise Value$1.65B
Total Cash (Recent Filing)$76.25M
Total Debt (Recent Filing)$56.99M
Price to Earnings (P/E)2.8
Beta0.53
Next Earnings
May 01, 2025EPS Estimate
-1.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.39
Shares Outstanding57,296,165
10 Day Avg. Volume254
30 Day Avg. Volume269
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)50.22
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit51.10
Enterprise Value/Ebitda-3.92
Forecast
1Y Price Target
$56.17Price Target Upside65.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Agios Pharma News
PremiumCompany Announcements
Agios Pharmaceuticals Reports Strong 2024 Financial Results
PremiumCompany Announcements
Agios Pharmaceuticals Earnings Call Highlights Growth & Pipeline Progress---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPhase 2 data from the RISE UP study in sickle cell disease have shown highly encouraging results, with superior hemoglobin increase and reduction in vaso-occlusive crises compared to competitors.
Product ExpansionMitapivat, the lead asset of Agios, is expected to have three approved indications by the end of 2026, expanding its potential market significantly.
Bears Say
Safety ConcernsConcerns over hepatocellular injury have negatively impacted AGIO stock, which is down approximately 45% due to these issues observed in thalassemia patients.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.50% Insiders
26.09% Mutual Funds
7.38% Other Institutional Investors
46.88% Public Companies and Individual Investors
0HB0 FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Agios Pharmaceuticals lowest share price was $27.37 and its highest was $62.60 in the past 12 months.
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is $1.84B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 50 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Feb 13, 2025. The company reported -$1.44 earnings per share for the quarter, beating the consensus estimate of -$1.691 by $0.251.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.78.
How many shares outstanding does Agios Pharmaceuticals have?
Agios Pharmaceuticals has 57,296,165 shares outstanding.
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of -$1.44 in its last earnings report, beating expectations of -$1.691. Following the earnings report the stock price went down -0.486%.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0HB0
---
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$56.17 (65.74% Upside)
$56.17 (65.74% Upside)
Blogger Sentiment
Bullish
GB:0HB0 Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.31%
12-Months-Change
Fundamentals
Return on Equity
57.29%
Trailing 12-Months
Asset Growth
77.48%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
---
0HB0 Company Deck
---
0HB0 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the development pipeline, with major milestones expected in thalassemia and sickle cell disease. Strong revenue growth from PYRUKYND and a robust financial position are positive indicators. However, higher operating expenses and limited revenue growth for PK deficiency were noted as challenges.Read More>---
0HB0 Stock 12 Month Forecast
Average Price Target
$56.17
▲(65.74% Upside)
Technical Analysis
Best Analysts Covering 0HB0
1 Year
1 Year Success Rate
14/25 ratings generated profit
1 Year Average Return
+15.74%
reiterated a buy rating 14 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 56.00% of your transactions generating a profit, with an average return of +15.74% per trade.
---